## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

HARBIGE et al Attv. Ref.: 604-706; Confirmation No. 1504

Appl. No. 10/756,761 TC/A.U. 1627

Filed: January 14, 2004 Examiner: Kantamneni, Shobha

For: TREATMENT OF NEURODEGENERATIVE CONDITIONS

May 25, 2010

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## SUPPLEMENTAL RESPONSE

This paper is supplemental to the Amendment filed on April 19, 2010. Attached for the Examiner's consideration is a Rule 132 declaration executed by Professor Giovannoni (the Giovannoni declaration).

The invention as claimed in claim 1 is directed to a method of treating a patient in need of therapy for multiple sclerosis (MS). The method comprises administering to that patient a therapeutically effective dose between 500mg/day and 700mg/day of a compound of formula I wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are independently selected from hydrogen, trihaloalkyl and halo substituents;  $X^1$ ,  $X^2$  and  $X^3$  are independently selected from CH, CCH<sub>2</sub>F, CCF<sub>3</sub>, CO alkyl, CCH<sub>3</sub>, and nitrogen, with at least two of  $X^1$ ,  $X^2$  and  $X^3$  being nitrogen; and  $Y^1$  and  $Y^2$  are independently selected from hydrogen, NH<sub>2</sub> and